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Abstract
Cancer of unknown primary (CUP) is defined as a heterogeneous group of tumours that present with metastasis, and in which 
attempts to identify the original site have failed. They differ from other primary tumours in their biological features and how 
they spread, which means that they can be considered a separate entity. There are several hypotheses regarding their origin, 
but the most plausible explanation for their aggressiveness and chemoresistance seems to involve chromosomal instability. 
Depending on the type of study done, CUP can account for 2–9% of all cancer patients, mostly 60–75 years old. This article 
reviews the main clinical, pathological, and molecular studies conducted to analyse and determine the origin of CUP.The 
main strategies for patient management and treatment, by both clinicians and pathologists, are also addressed.
Keywords Cancer of unknown primary · Diagnosis · Immunohistochemistry · Biopsy · Prognosis · Chemotherapy · 
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Introduction
Cancer of unknown primary (CUP) is defined as a heteroge-
neous group of tumours that present initially with metastasis, 
and in which a properly standardised diagnostic work-up 
cannot identify the original site of the malignancy [1, 2]. In 
the last few years, various consensus statements and inter-
national clinical guidelines have tried to define more clearly 
what diagnostic work-up should be performed before a case 
is regarded as CUP. The US National Cancer Institute (NCI), 
the National Comprehensive Cancer Network (NCCN), and 
the European Society of Medical Oncology (ESMO) have 
published minimum recommendations on this subject, with 
a reminder that any cancer presenting with metastasis must 
undergo the initial testing before being regarded as CUP 
[3, 4].
CUP can be considered a separate entity, because its 
biological properties set it apart from other known primary 
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tumours. In addition, it generally has atypical patterns of 
spread and clinical behaviour, which are inconsistent with 
the supposed site of origin [5]. There are two hypotheses 
regarding CUP biology: the first suggests that the neoplasm 
might arise from a stem cell, without first producing a pre-
malignant lesion or a primary tumour; the second maintains 
that it represents rapid progression of metastasis from a very 
early primary tumour [6].
Chromosomal instability was recently suggested as a 
plausible explanation, or even a prognostic factor for more 
aggressive presentation and chemoresistance of CUP [7]. 
It has been shown that, generally, CUP is not associated 
with specific mutations in oncogenes or suppressor genes. 
Instead, it is characterised by angiogenesis activation 
(50–89%), oncogene over-expression (10–30%), a greater 
presence of hypoxia-related proteins and epithelial–mesen-
chymal transition markers (16–25%), and the activation of 
intracellular signals such as AKT or MAPK (20–35%) [8].
Depending on the definition used and how exhaustive 
the diagnostic procedures are, CUP can account for 2% to 
9% of all cancer patients [1]. Accordingly, the incidence of 
CUP may change as new diagnostic technologies are imple-
mented. In purely numerical terms, CUP is currently the 
eighth most frequent cancer diagnosis [1]. Its incidence is 
highest in patients aged 60–75 years [9, 10]. The most com-
mon underlying occult primary tumours are basically of lung 
and biliopancreatic origin, as observed in the pooled analysis 
of over 800 patients in 12 autopsy series [11].
Basic clinical work‑up
The initial clinical assessment of patients diagnosed with 
CUP should not be exhaustive. Instead, it should aim to 
determine the extent of the disease, and to identify tumour 
subtypes in which a specific therapy may have a positive 
impact on patient progress and prognosis. The basic clinical 
investigations that should be done include history-taking and 
physical examination, basic laboratory tests, and computed 
tomography (CT) of the chest, abdomen, and pelvis.
A full medical history and physical examination should 
include genitourinary and rectal examination, as well as 
examining the breasts and pelvic region in women, and 
the prostate in men. Special attention should be paid to the 
previous diseases, biopsies or lesions removed, spontane-
ously regressing lesions, previous imaging tests, and family 
cancer history. The laboratory tests recommended are a full 
blood count with differential white cell count, measurement 
of electrolytes, creatinine and calcium, liver function tests, 
and basic urinalysis [4, 12].
Serum tumour markers should not be tested routinely. 
Elevations in these markers are not highly sensitive or spe-
cific, and testing for them during CUP diagnosis has not 
been shown to be cost-effective. In men, however, tests 
for prostate-specific antigen (PSA), serum chorionic gon-
adotropin (β-hCG), and alpha-fetoprotein (AFP) are recom-
mended, to rule out treatable extragonadal germ cell tumours 
or prostate cancer eligible for endocrine therapy. In the case 
of adenocarcinomas with peritoneal involvement in women, 
a CA 125 test should be done [2, 13].
As far as the initial radiological tests are concerned, 
patients should have a contrast-enhanced CT scan of the 
chest, abdomen, and pelvis. If there are cervical lymphad-
enopathies, this should be accompanied by a CT scan of the 
neck. Positron emission tomography (PET) can be useful in 
certain clinical presentations, for both diagnosis and staging 
[14]. It has 87% sensitivity and 71% specificity [15]. One 
of the limitations of PET is its moderate precision regard-
ing anatomical sites or functional abnormalities, because of 
low tracer uptake by some tumour tissues. In these cases, it 
is more helpful to combine PET with CT. A meta-analysis 
and systematic review of combined PET/CT in patients diag-
nosed with CUP found that primary tumours were detected 
in 37% of patients, with 84% sensitivity and identical 84% 
specificity [16]. This primary tumour detection rate is higher 
in the case of specific metastatic scenarios, such as cervical 
lymphadenopathies, and sensitivity is higher too [17]. How-
ever, in the only prospective study done, PET/CT proved no 
superior to CT [18]. PET is, therefore, not recommended as 
the initial test. Its use should be confined to specific clini-
cal presentations (single metastases and cervical lymphad-
enopathies), and when local or regional therapy is being 
considered.
In women, it is helpful to perform mammography, and/
or magnetic resonance imaging of the breasts if the mam-
mography result is equivocal [13]. On the other hand, endos-
copy should not be routinely employed, because it rarely 
detects the primary tumour in asymptomatic patients, and 
false positives can cause confusion [19]. The choice of other 
diagnostic procedures should be based on interpretation of 
the histological sample obtained by biopsy.
Pathological diagnosis
Optimising the sample
Obtaining a sample of enough tissue is essential for diagnos-
ing and investigating CUP, both for tumour typing and for 
conducting additional molecular studies. The sample should 
be obtained using a procedure that provides as much tissue 
as possible but is not highly invasive for the patient [20]. 
Although the minimum number of cells needed for histo-
logical and molecular investigations is not well established, 
samples containing at least 400 cells are recommended 
[21]. Some studies show that cytology specimens can be 
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diagnostically useful [22, 23]. To enable all the necessary 
tests to be done, however, solid tissue samples obtained by 
core-needle biopsy (CNB), incisional biopsy, or surgical 
resection are preferable.
On the other hand, it is essential to optimise the material 
obtained. The available material should be divided between 
multiple paraffin blocks, to conserve as much tissue as pos-
sible. Diagnostic immunohistochemical tests should be con-
fined to reasonable panels, according to the available clinical 
and radiological evidence, to prevent unnecessary staining. 
In cases likely to require molecular techniques, it is advis-
able to prepare a few blank slides when serial sections are 
cut for routine immunostaining.
Basic histopathology study and classification 
by morphological/histopathological subtype
After the initial clinical assessment, the sample is examined 
using histopathological techniques, which may require a 
basic immunohistochemical (IHC) panel. Preliminary clas-
sification then becomes possible [2, 24–26]:
Initial classification
The most common initial classifications are:
• Carcinoma/neuroendocrine tumour:
– adenocarcinoma (60%);
– poorly differentiated carcinoma, including poorly dif-
ferentiated adenocarcinoma (20%);
– squamous cell (epidermoid) and/or transitional cell 
carcinoma (5–10%);
– neuroendocrine tumour (5%);
– undifferentiated carcinoma;
• lymphoma;
• extragonadal germ cell tumour;
• melanoma;
• sarcoma.
In this first classification, it should be remembered that 
CUP may be due to tumours of atypical site, morphology, 
and immunophenotype. The most common metastases at that 
site have to be ruled out. Tumours that have effective spe-
cific therapies must also be appropriately excluded, such as 
germ cell tumours, neuroendocrine tumours, lymphoma, and 
hormone-dependent tumours (prostate in men and breast in 
women). Moreover, IHC markers may have limited specific-
ity and sensitivity in this first classification.
General histopathological patterns
The general histopathological patterns are as follows:
• Epithelial/epithelioid: carcinoma, “epithelioid” sarcoma, 
and melanoma;
• Spindle cell: sarcoma, sarcomatoid carcinoma, and mela-
noma;
• Small cell: lymphoma, sarcoma, neuroendocrine tumour, 
primitive neuroectodermal tumour (PNET), and mela-
noma;
• Pleomorphic: all.
Second classification: most likely primary tumour
In poorly differentiated carcinomas and adenocarcinomas, 
immunohistochemistry is essential. In squamous cell car-
cinomas, morphology and immunohistochemistry are rela-
tively non-specific, although there are subtypes associated 
with human papillomavirus that have greater specificity.
In some cases, relevant differences may exist between 
primary tumours and their metastases. For example, com-
pared with primary tumours, melanoma metastases show 
greater cytokeratin (CK) AE1/AE3 staining (22%) and less 
HMB45 staining (65%). The marker S100 may be expressed 
in adenocarcinomas of the lung, breast, endometrium, and 
kidney (up to 80%), and other sites to a lesser extent [27].
Certain epithelioid or spindle cell sarcomas can be con-
fused with carcinomas or melanomas. Many sarcomas have 
specific molecular alterations that can be demonstrated by 
immunohistochemistry or fluorescence in situ hybridisation 
(FISH) [28]. Molecular diagnostics are particularly recom-
mended for sarcomas of atypical morphology or site.
Prognostic classification of CUP
The prognosis is favourable in 15–20% of CUP cases [24, 
25]. These tumours are more chemosensitive and overall 
survival is better. This category includes poorly differenti-
ated midline carcinomas, peritoneal papillary adenocarci-
nomas in women, metastatic adenocarcinoma involving the 
axillary lymph nodes only, metastatic squamous cell carci-
noma in the cervical lymph nodes, single-node metastases, 
poorly differentiated neuroendocrine carcinoma, resectable 
tumours, and germ cell tumours. In contrast, other cases of 
CUP have a poor prognosis. These include adenocarcinomas 
with liver metastases, non-papillary malignant ascites, and 
multiple brain, bone, or lung metastases.
Specific histopathology study
Advisable minimum IHC panel
The initial IHC panel should be based on the patient’s clini-
cal details (age, sex, disease history, site, etc.) and morpho-
logical examination of the mass. For a general approach to 
CUP, the basic IHC panel should mainly consist of epithelial 
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cell markers (CK AE1/AE3, CK Cam 5.2, EMA), S100, 
vimentin, and leucocyte common antigen (LCA or CD45) 
(Fig. 1). If epithelial origin of the lesion is confirmed (CK+ , 
S100−, vimentin ± and LCA−), a combination of CK7 and 
CK20 will give a first indication of the organ in which the 
tumour is most likely to have originated [29].
In general, although carcinomas express CK and mes-
enchymal tumours express vimentin, the exceptions to that 
rule must be remembered. For example, poorly differentiated 
carcinomas can show an unpredictable CK expression pat-
tern, or CK expression may be lost completely (as in cases 
involving the kidney or adrenal gland), whereas some carci-
nomas co-express vimentin and CK (typically those found 
in the endometrium, thyroid, and kidney, among others). 
On the other hand, some types of sarcoma, such as epithe-
lioid or synovial sarcomas, leiomyosarcomas or malignant 
peripheral nerve sheath tumours, can co-express vimentin 
and CK. This also occurs in polyphenotypic tumours/blas-
tomas, such as Ewing sarcoma/PNET, desmoplastic small 
round cell tumour, or medulloblastoma.
Staining positive for CD45 and negative for CK suggests 
a lesion of haematological origin, although some haematol-
ymphoid tumours (granulocytic sarcoma, myelomas, Hodg-
kin’s lymphoma, or anaplastic lymphomas) may have very 
little or no CD45 expression and test positive for S100 or 
EMA. S100 is highly specific for lesions of melanocytic or 
neural origin and may be expressed in a nuclear and cyto-
plasmic pattern. Vimentin is an intermediate filament char-
acteristic of mesenchymal cells. It is found in almost all 
sarcomas, melanomas, and a good proportion of lymphomas. 
It tends to play a supportive role together with other markers.
The detection of tumours with neuroendocrine differenti-
ation and tumours of germ cell origin deserves special men-
tion. For neuroendocrine tumours, the panel should include 
synaptophysin, chromogranin A, and CD56. For germ cell 
tumours, a specific panel should be considered, such as 
PLAP, alpha-fetoprotein, or OCT 3/4. When the tumour’s 
microscopic features show it to be clearly epithelial, some 
of the markers in this profile can be omitted. In that case, the 
initial panel can be restricted to CK7 and CK20, and testing 
completed with the extended panel.
Optional extended IHC panel
First, the following points should be considered. Tumour 
types with widely differing phenotypic profiles arise in each 
organ. Therefore, this article refers to the most common and 
most clinically relevant in each case. Phenotypic profiles of 
tumours of the same origin and histological type vary from 
one case to another, according to their degree of differentia-
tion, and as they progress. This article, therefore, always 
refers to expression patterns in general, on the understand-
ing that each particular case may display atypical, aberrant, 
or exceptional phenotypes. As markers can be identified in 
tumours of different histological types arising in different 
organs, and practically no absolutely specific markers exist, 
it is advisable to test for several markers simultaneously to 
reach a conclusive diagnosis.
Fig. 1  Advisable minimum IHC 
panel. IHC immunohistochem-
istry
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Once a first approximation has been obtained using an 
initial panel (Fig. 1), combined with clinical details (age, 
gender, past medical and family history, lesion site, bio-
chemistry, imaging, etc.) and the tumour’s histological pat-
tern, thereby confirming that it is a carcinoma and that other 
tumour types (melanomas, lymphomas, germ line malignan-
cies, etc.) can reasonably be ruled out, specific expression 
patterns should be studied (Table 1).
Molecular diagnostics
Thanks to advances in immunohistochemistry, the propor-
tion of CUP cases in which the origin cannot be identified 
has fallen to 15–20%. This is the patient group most reliant 
on the use of molecular platforms. Molecular techniques 
offer information for possible specific therapy. Strategies fall 
into two categories: platforms for identifying the organ har-
bouring the primary tumour; and next-generation sequencing 
to characterise the tumour’s mutation profile.
Platforms for identifying the organ harbouring 
the primary tumour
Various molecular platforms exist for evaluating gene 
expression, microRNA profile or epigenetic pattern in 
CUP [30–38]. Once a tumour’s molecular profile has been 
obtained, it is compared against database results from a 
range of sites and histological types. The molecular profile 
of the tumour being tested is assessed for similarity to these 
patterns, and the diagnosis provided suggests one or more 
sites, each with its estimated probability (similarity score). 
Table 2 lists the main features of these platforms. The choice 
of one platform over another depends on several factors, 
such as availability in different countries. Strategies of more 
recent introduction tend to be more informative, because 
they analyse a larger number of possible sites.
In general, these platforms correlate well with immu-
nohistochemistry, and reduce the number of CUP cases in 
which the primary cannot be identified. The main difficulties 
involved in using them are: (1) detecting unusual tumours 
Table 1  Main phenotypic profiles of the most common tumours
Underlining indicates markers recommended for their greater specificity and usefulness
Tumour Markers
Breast GATA3, mammaglobin, GCDFP-15, hormone receptors (oestrogens, progesterone, and 
androgens), CA 15-3, CK34BE12
Salivary gland Like breast, GFAP
Skin appendages Like breast, S100
Thyroid PAX8, TTF1, thyroglobulin
Parathyroid PTH, GATA3, synaptophysin, chromogranin A
Lung (non-mucinous adenocarcinoma) TTF1, napsin A, CEA
Lung (mucinous adenocarcinoma) TTF1, napsin A, CDX2, SATB2-, cadherin 17-, CEA
Cervix (squamous cell) p40, p63, p16, HPV + , PAX8, 34BE12
Endocervix CEA, p16, ER/PR-, HPV + , PAX8, vimentin-
Endometrium PAX8, ER/PR, vimentin, CEA-, WT1-, CA 125
Ovary/fallopian tube (serous) PAX8, WT1, ER/PR, vimentin, CA 125
Ovary (endometrioid) PAX8, ER/PR, vimentin, CA 125
Ovary (mucinous) PAX8, CDX2, WT1-, SATB2-, cadherin 17-, TTF1-
Mesothelium calretinin, WT1, CK5/6, vimentin, podoplanin (D2-40), CEA-
Colon/rectum CDX2, SATB2, cadherin 17, villin, AMACR, CEA, CA 19-9
Small intestine CDX2, cadherin 17, SATB±
Pancreas/bile ducts CDX2, CK17, cadherin 17, SATB2 ± , CEA, CA 19-9, DPC4-
Stomach CDX2, CK17-, cadherin 17, SATB±
Liver arginase-1, Hep Par1, glypican 3
Kidney PAX8, RCC, carbonic anhydrase IX, glutathione reductase, vimentin, CD10, AMACR, c-KIT
Adrenal SF1, melan-A, inhibin alpha, synaptophysin, chromogranin A, calretinin
Prostate NKX3, PSA, AMACR , AR, prostatic acid phosphatase
Squamous cell carcinomas p40, p63, 34BE12, p16/p53, HPV, MMP-13
Transitional cell carcinomas p40, p63, GATA3, uroplakin II, S100P, CK34BE12 + , CK8/18
Myoepithelial carcinomas p63, CK34BE12, myosin, EMA, S100, GFAP, CD10
Neuroendocrine tumours synaptophysin, chromogranin A, CD56/CD57, PGP9.5, neurofilaments
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not always covered by the platforms, e.g., uncommon sites 
or exceptional histological types; (2) distinguishing between 
tumours of similar morphology or origin, that may have very 
similar molecular traits but different oncological manage-
ment; and (3) to date, these platforms are not funded by the 
national health system.
The results of these molecular techniques are highly 
dependent on the quantity, quality, and percentage of tumour 
cells. Strategies, therefore, need to be established for obtain-
ing optimal material and preserving it after immunohisto-
chemical testing has taken place.
There are a few prospective studies to support the useful-
ness of these platforms. In a study involving 194 patients, 
Hainsworth et al. showed that survival was better when the 
platform predicted tumour types clinically associated with 
a better response [39]. In general, molecular platforms are 
regarded as complementary to immunohistochemistry, and 
useful when a reasonable number of immunohistochemi-
cal stains have failed to predict tumour origin, especially in 
poorly differentiated tumours [34].
Next‑generation sequencing to characterise 
the tumour’s mutation profile
Sequencing with gene panels enables mutations associated 
with responses to specific drugs (actionable mutations) to 
be identified. This strategy has been tested in several stud-
ies. Gatalica et al. evaluated 1806 CUP cases by immuno-
histochemistry (23 markers), sequencing (47 genes) and 
in situ hybridisation (7 genes) [40]. They found actionable 
alterations in 96% of cases. In another study, Ross et al. 
studied formalin-fixed, paraffin-embedded specimens from 
200 patients with CUP, 125 of whom had adenocarcinomas 
[41]. These authors examined 236 genes and the introns of 
19 genes often altered in cancer. At least one actionable 
mutation was identified in 96% of cases. Tothill et al. used 
panels representing 701 genes and identified actionable 
mutations in 12 out of 16 cases [42].
The main objection to using massively parallel sequenc-
ing in CUP arises from the belief that the potential drug 
response conferred by a given mutation depends on the 
type of tumour in which the mutation is found. That is, the 
context of histological type and tumour site can affect the 
response to the drug [43]. That assumption is based on stud-
ies such as the SHIVA study, which showed that molecularly 
targeted off-label drug use failed to improve patients’ dis-
ease-free survival [44]. Accordingly, sequencing techniques 
are complementary to platforms for predicting the primary 
cancer site.
Targeted clinical work‑up and prognosis
The median survival of patients with CUP is approximately 
9–10 months, similar to that seen in metastatic lung cancer 
[45]. A gradual increase has been detected in CUP survival, 
probably because of improved therapy for malignancies of 
known origin and better management of metastatic disease, 
as well as optimisation of diagnostic resources in general 
[46].
Nevertheless, patients who present with metastasis of 
a known tumour have better survival than patients whose 
primary tumour is unknown [47]. Successfully identifying 
tumour origin improves the patient’s prognosis, probably 
because it enables better treatment selection and adjust-
ment [48]. That was demonstrated in patients whose CUP 
molecular profiling results proved consistent with colorectal 
cancer, and who were treated accordingly (median survival 
27 months and 50% response to specific therapy, similar to 
figures obtained in colon cancer) [49]. Therefore, the factor 
most likely to improve the prognosis of a patient with CUP 
is actually not having CUP any more. That is why the algo-
rithm for diagnosing and managing CUP looks for “great-
est similarity” to known tumours, in terms of IHC, clinical 
features, and/or molecular findings.
In the absence of a definitive diagnosis, the clinical work-
up should aim to identify tumours that can be treated accord-
ing to consensus guidelines because of similarity to known 
primary tumours [2, 25, 50]. Patients with “favourable” 
CUP have a better prognosis. These cases should be treated 
with locoregional or systemic therapies, because the sur-
vival achieved will be longer and/or similar to their known 
homologues [51] (Table 3). Unfortunately, these patients 
only account for 22–23% of cases [52].
The remainder are categorised in the “unfavourable” CUP 
group, and their prospects depend on various prognostic 
factors. Their median survival ranges from 3 to 10 months. 
Clinical, laboratory, and histological prognostic factors 
have been documented. Poor clinical prognostic factors 
of particular note are: presenting with multiple metastases 
(especially at more than 3 sites); and liver, bone, or adrenal 
Table 2  Main molecular diagnostics platforms for cancer of unknown 
primary
a Platforms available in Spain
Platform Method No. of genes Sensitivity (%)
Quest-Lab RT-PCR 92 –
Veridex RT-PCR 6 76.0
Pathwork cDNA array 2000 89.0
Cup-print cDNA array 495 85.0
Rosetta miRNA array 64 90.0
CancerTypea RT-PCR 92 89.0
Epicupa methylation array – 97.7
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metastases [53, 54]. Single sites confer a better prognosis, 
as do lymph node metastases with no visceral involvement 
[45]. If only lymph nodes are affected, patients with just the 
cervical, axillary, and/or inguinal lymph nodes involved have 
a better prognosis than those with lymph node metastases 
in pelvic or abdominal locations. Other factors that worsen 
the prognosis are impaired performance status and previous 
weight loss [55, 56].
As far as laboratory tests are concerned, common poor 
prognostic factors are mainly increased lactate dehydro-
genase (LDH) and hypoalbuminemia, probably related to 
weight loss [55, 56]. In terms of haematological findings, 
leucocytosis and anaemia also constitute independent poor 
prognostic factors [57]. It is possible that the “inflamma-
tion-based” Glasgow Prognostic Score, calculated from the 
neutrophil/lymphocyte ratio (NLR), may predict with more 
certainty how a particular case will behave [58].
Among histological factors, adenocarcinomas and undif-
ferentiated tumours have a worse prognosis (3.5% 3-year 
survival) than squamous cell carcinomas (41.6% 3-year sur-
vival) [59].
Petrakis et al. described a prognostic algorithm based on 
factors that, in their series, independently affected patient 
survival (Ioannina Score for CUP Outpatient Oncologic 
Prognostication, I-SCOOP). Those factors were: leucocy-
tosis, CUP subset (visceral disease), and performance status 
[60]. Using advanced statistical methods, they constructed 
an algorithm that gave a 5-tier point score. This enabled 
patients to be categorised into three risk levels: low, inter-
mediate, and high. Other algorithms have been published 
by various authors, but no consensus has ever been reached, 
probably because of the heterogeneous nature of the cases 
included in each series.
Treating cancer of unknown primary
Treatment strategies for CUP are quite challenging, because 
these malignancies represent an extremely heterogeneous 
group of metastatic tumours with, in general, a dismal prog-
nosis. Nevertheless, some subsets of CUP patients, who may 
harbour chemosensitive and potentially curable tumours, 
have a favourable risk (about 20%) [25]. Favourable-risk 
CUP can be identified on the basis of clinical and patho-
logical features, so every effort should be made to identify 
such cases.
To establish a rational approach to treatment in this sce-
nario, two main groups can be identified: a) CUP in which 
Table 3  Favourable cancers of unknown primary and specific therapy
AFP alpha-fetoprotein, CK cytokeratin, CT chemotherapy, ER oestrogen receptors, hCG human chorionic gonadotropin, IHC immunohisto-
chemistry, LND lymph node dissection, M1 metastasis, MRI magnetic resonance imaging, PET positron emission tomography, PR progesterone 
receptors, PSA prostate-specific antigen, RT radiotherapy
a Breast cancer: females with adenocarcinoma and axillary lymphadenopathy should be treated as if they had stage II breast cancer
b Ovarian cancer: females with peritoneal carcinomatosis should be treated as if they had stage III ovarian cancer, especially in the case of raised 
CA 12.5, known adenocarcinoma histology, and if gastrointestinal origin has been ruled out
c Prostate cancer: males with blastic bone metastases and raised serum prostate-specific antigen should be treated as if they had metastatic pros-
tate cancer
d Colorectal cancer: patients whose clinical and pathological features are consistent with a primary colorectal tumour should be treated using 
the same protocols as for metastatic colorectal cancer, especially in the case of known adenocarcinoma histology and CK20+/CK7- or CDX2+ 
immunohistochemical staining
e Tumours of the head and neck, and anogenital tumours: in patients with squamous cell carcinoma involving the cervical or inguinal lymph 
nodes only, locoregional approaches based on chemotherapy/radiotherapy strategies are warranted
f Extragonadal germ cell tumours: young males with poorly differentiated mediastinal or retroperitoneal tumours should be treated as if they had 
extragonadal germ cell tumours
Histology Clinical subset Further investigation Therapy
Adenocarcinoma Female + axillary lymphadenopathies Breast MRI ER/PR/HER-2 = Breast  cancera
Female + peritoneal carcinomatosis CA 12.5 = Ovarian  cancerb
Male with blastic bone M1 and raised PSA PSA = Prostate  cancerc
Clinical/pathological features consistent with a 
primary colorectal tumour
IHC: CK20 +/CK7- and CDX2+ = Colon  cancerd
Single M1 lesion PET Local therapy ± CT
Squamous cell Cervical lymph nodes Endoscopy/PET?
Tonsillectomy
= Head and neck  cancere
Inguinal lymph nodes LND ± RT ± CT
Undifferentiated Young male, mediastinum and/or retroperitoneum hCG, AFP = Extragonadal germ cell  cancerf
Neuroendocrine Low or high grade Octreotide scan = Neuroendocrine tumour
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the primary site of tumour origin is strongly suspected from 
the clinical and pathological features; and b) tumours for 
which no suspicion can be formulated regarding the origin 
of the primary tumour [2] (Fig. 2).
In the first case, the treatment plan should be based on the 
same standard strategies established for tumours thought to 
be primaries [2, 61] (Table 3). As well as the subsets men-
tioned above, other cases of CUP inviting no suspicions as 
to primary origin may show a favourable prognosis. That is 
true of the following patient subsets:
(a) Poorly differentiated malignancies: up to 60% of these 
cases are accounted for by lymphomas, which can be 
suspected on detection of widespread involvement of 
lymph node territories and organs, such as the liver, and 
especially the spleen. In these cases, it can be useful 
to conduct appropriate analysis, including a PET scan 
and repeated biopsies, if feasible, to guide the use of 
specific therapies [61].
(b) Involvement of a single site: locoregional strategies, 
including surgery, is highly advisable. The use of PET 
is strongly recommended in this situation, provided not 
only that limited locoregional CUP is suspected, but 
also that treatment with curative intent is feasible [3].
(c) Low/intermediate/high-grade neuroendocrine tumours: 
these tumours represent a heterogeneous group of 
malignancies. Well-differentiated neuroendocrine 
tumours (low and intermediate grades) share similar 
approaches to diagnosis and treatment. Clinical syn-
dromes may be displayed due to production of hor-
mones or vasoactive substances. Low-grade tumours 
are often slow-growing, so managing them like well-
differentiated neuroendocrine tumours of the gastro-
intestinal tract is recommended. At advanced stages, 
the preferred approach is simple observation (asympto-
matic patients) or symptomatic treatment with somato-
statin analogues (octreotide). Intensive platinum-based 
chemotherapy seems unhelpful in this context [62]; 
however, sunitinib or everolimus therapy may be con-
sidered when a functioning pancreatic neuroendocrine 
tumour is suspected [63, 64]. On the other hand, poorly 
differentiated neuroendocrine tumours are always 
high-grade tumours (grade 3), with aggressive clinical 
behaviour and a poor prognosis. These tumours require 
rapid evaluation and therapy. They typically respond 
to chemotherapy, so they are treated like disseminated 
small cell lung cancer. The treatment of choice is 
chemotherapy cycles of cisplatin and etoposide. This 
provides overall response rates in the 70–80% range. 
Other more intensive regimens show a similar response 
rate but have greater toxicity [62].
Although more consistent evidence is needed, retrospec-
tive studies have revealed that favourable-risk CUP patients 
show clinical behaviour and responses resembling those seen 
in patients with metastatic tumours of known primary origin 
[65]. The great majority of CUP patients are categorised 
in the poor-risk subset. Unfortunately, these patients share 
Fig. 2  Summary of proposed 
management of cancer of 
unknown primary
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a rather dismal prognosis, with median overall survival of 
8–12 months from diagnosis [66]. Chemotherapy combina-
tions studied in this context show no evidence of superiority 
using any regimen [67]. Most of the combinations tested 
have been based on platinum salts (cisplatin, carboplatin, 
and oxaliplatin) with other drugs (taxanes, gemcitabine, 
etoposide, irinotecan, etc.) [68, 69]. However, very mod-
est outcomes have been documented with this approach. It 
provides symptom relief at best, with no clear overall impact 
on survival confirmed. Because of its high toxicity and rel-
atively low efficacy in CUP, chemotherapy should always 
be used judiciously, once other potentially more effective 
options have been reasonably ruled out (Fig. 2).
In the era of personalised medicine, efforts have also been 
made to confirm whether there may be a role for targeted 
therapies in CUP management. The modern gene expres-
sion profile assays on the market can identify the origin of 
CUP tissues in up to 80% of cases [32]. One method for 
elucidating the origin of a tissue is to select a therapy of 
proven effectiveness in a class of tumours, and/or to use 
that information to implement personalised therapies in each 
patient. This has not yet been tested in clinical trials, but a 
Phase III prospective trial is being conducted (GEFCAPI04, 
clinicaltrials.gov NCT01540058).
As well as determining tissue origin based on tumour 
tissue samples, another promising strategy involves liquid 
biopsies that detect circulating tumour DNA in patients with 
CUP. In a recent study of 442 CUP patients, liquid biopsy 
detected a genomic alteration in 65.6% of cases. The most 
common mutations were in TP53, KRAS, and PIK3CA [70]. 
EGFR abnormalities, ERBB2 alterations, and BRAF V600E 
mutations were found in 5.9, 3.6, and 1.6% of cases, respec-
tively. Changes in a mismatch repair (MMR) gene were 
also detected in 1.6% of cases, making immune checkpoint 
inhibitor therapy an option. A trial is currently in progress 
using pembrolizumab in patients with rare tumours, includ-
ing CUP (clinicaltrials.gov NCT02721732). As well as 
MMR mutations, other promising biomarkers that may help 
with immunotherapy, such as tumour mutational burden, are 
being tested intensively and may play an important role in 
CUP treatment strategies [71].
Conclusions
Because of the biological features of CUP, the way in which 
it spreads, and its aggressive, chemoresistant nature in some 
cases, it is very important to diagnose it promptly and accu-
rately. Attempts should be made to determine its extent and 
identify the tumour subtype to which it belongs, to enable 
use of a specific therapy that has a positive impact on the 
patient. However, identifying the origin of these tumours is 
not easy, especially because the same organ can give rise to 
different tumour types, and tumours with the same origin 
can vary in phenotypic profile from case to case. Moreover, 
the literature evidence is sometimes confusing or contradic-
tory, because the diagnostic methods used are not always 
the same, and results may be interpreted in different ways. 
It is, therefore, important to have standardised protocols for 
diagnosis and interpretation of the results.
On the other hand, it is important to obtain a good biopsy, 
ensuring adequate numbers of tumour cells, and to plan 
tissue use to obtain as much information as possible. The 
algorithm proposed by the Spanish Society of Pathology 
(SEAP) is shown in Fig. 3. The recommendation is to use a 
basic IHC panel based on the tumour’s clinical and micro-
scopic features, and a specific advanced IHC panel. A lim-
ited number of techniques should be performed with both 
panels, so that a suitable amount of tissue is preserved for 
using a molecular platform, if thought necessary. Molecular 
diagnostics and gene expression platforms are considered 
helpful when used to complement IHC testing, because the 
results which they provide can be compared against many 
databases, allowing more accurate diagnosis and specifica-
tion of tumour origin.
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